title: Applying proteomic technology to clinical virology.
abstract: Developing antiviral drugs, vaccines and diagnostic markers is still the most ambitious challenge in clinical virology. In the past few decades, data from high-throughput technologies have allowed for the rapid development of new antiviral therapeutic strategies, thus making a profound impact on translational research. Most of the current preclinical studies in virology are aimed at evaluating the dynamic composition and localization of the protein platforms involved in various host-virus interactions. Among the different possible approaches, mass spectrometry-based proteomics is increasingly being used to define the protein composition in subcellular compartments, quantify differential protein expression among samples, characterize protein complexes, and analyse protein post-translational modifications. Here, we review the current knowledge of the most useful proteomic approaches in the study of viral persistence and pathogenicity, with a particular focus on recent advances in hepatitis C research.
authors.affiliation: 'Lazzaro Spallanzani' National Institute for Infectious Diseases I.R.C.C.S.; Department of Cellular Biotechnologies and Haematology, Istituto Pasteur-Fondazione Cenci Bolognetti, Sapienza University of Rome. Electronic address: tripodi@bce.uniroma1.it.
authors.forename: C
authors.initials: C
authors.lastname: Mancone
authors.affiliation: 'Lazzaro Spallanzani' National Institute for Infectious Diseases I.R.C.C.S.
authors.forename: F
authors.initials: F
authors.lastname: Ciccosanti
authors.affiliation: 'Lazzaro Spallanzani' National Institute for Infectious Diseases I.R.C.C.S.; Department of Cellular Biotechnologies and Haematology, Istituto Pasteur-Fondazione Cenci Bolognetti, Sapienza University of Rome.
authors.forename: C
authors.initials: C
authors.lastname: Montaldo
authors.affiliation: 'Lazzaro Spallanzani' National Institute for Infectious Diseases I.R.C.C.S.
authors.forename: A B
authors.initials: AB
authors.lastname: Perdomo
authors.affiliation: 'Lazzaro Spallanzani' National Institute for Infectious Diseases I.R.C.C.S.; Department of Biology, University of Rome 'Tor Vergata', Rome, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Piacentini
authors.affiliation: 'Lazzaro Spallanzani' National Institute for Infectious Diseases I.R.C.C.S.
authors.forename: T
authors.initials: T
authors.lastname: Alonzi
authors.affiliation: 'Lazzaro Spallanzani' National Institute for Infectious Diseases I.R.C.C.S.
authors.forename: G M
authors.initials: GM
authors.lastname: Fimia
authors.affiliation: 'Lazzaro Spallanzani' National Institute for Infectious Diseases I.R.C.C.S.; 'Lazzaro Spallanzani' National Institute for Infectious Diseases I.R.C.C.S.
authors.forename: M
authors.initials: M
authors.lastname: Tripodi
mesh_terms: D016174:Hepacivirus / Q000378:metabolism; D006526:Hepatitis C / Q000821:virology; D054884:Host-Pathogen Interactions; D006801:Humans; D040901:Proteomics / Q000379:methods*; D014773:Virology / Q000379:methods*